news report
NCI Offers Checkpoint-Resistant Cancer Cell Line for Licensing
The CRISPR-engineered mouse colon-cancer model removes B2m and MHC-I antigen presentation to support preclinical research on resistance to PD-1 and PD-L1 therapies.
topics
Cancer immunotherapy